Paradoxical effect of 2,3-dimercapto-1-propanesulfonic acid (DMPS) on enhancing antitumor activity of cisplatin in ascites sarcoma 180 cells

Journal of Pharmacological Sciences

Volumn 112, Issue 3, 2010, Pages 361-368

  Sato, Toshihiro ^a   Okubo, Migiwa ^a   Sawaki, Kohei ^a   Maehashi, Hiroshi ^b   Kawaguchi, Mitsuru ^a  

^a TOKYO DENTAL COLLEGE   (Japan)

^b MATSUMOTO DENTAL UNIVERSITY   (Japan)

Author keywords

2,3 dimercapto 1 propanesulfonic acid (DMPS); Antitumor activity; Cisplatin; Meso 2,3 dimercaptosuccinic acid (DMSA); Sarcoma 180 cell

Indexed keywords

CALCIUM; CISPLATIN; PLATINUM; SUCCIMER; THYMIDINE; UNITHIOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; SARCOMA 180; SARCOMA CELL;

EID: 77950638092     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09323FP     Document Type: Article

References (35)

1. Gur'yanov BM, Kolodyazhnyi VL. Prophylactic action of unithiol during experimental lead poisoning. Farmakol Toksikol. 1971;34:168-171.
2. Okonishnikova IE, Rozenberg EE, Rezina IA. Therapeutic and prophylactic action of succimer in experimental subacute lead acetate poisoning. Gig Tr Prof Zabol. 1976;8:24-28.
3. Bratton GR, Zmudzki J, Bell MC, Warnock LG. Thiamin (vitamin b1) effects on lead intoxication and deposition of lead in tissues: therapeutic potential. Toxicol Appl Pharmacol. 1981;59: 164-172.
4. Planas-Bohne F, Olinger H. The interaction of chelating agents with methylmercuric chloride bound to erythrocytes. Biochem Pharmacol. 1981;30:667-669.
5. Planas-Bohne F. The influence of chelating agents on the distribution and biotransformation of methylmercuric chloride in rats. J Pharmacol Exp Ther. 1981;217:500-504.
6. George GN, Prince RC, Gailer J, Buttigieg GA, Denton MB, Harris HH, et al. Mercury binding to the chelation therapy agents DMSA and DMPS and the rational design of custom chelators for mercury. Chem Res Toxicol. 2004;17:999-1006.
7. Bridges CC, Joshee L, Zalups RK. Multidrug resistance proteins and the renal elimination of inorganic mercury mediated by 2,3-dimercaptopropane-1-sulfonic acid and meso-2,3-dimercaptosuccinic acid. J Pharmacol Exp Ther. 2008;324:383-390.
8. Jones MM, Weaver AD, Weller WL. The relative effectiveness of some chelating agents as antidotes in acute cadmium poisoning. Res Commun Chem Pathol Pharmacol. 1978;22:581-588.
9. Cantilena LRJr, Klaassen CD. Comparison of the effectiveness of several chelators after single administration on the toxicity, excretion, and distribution of cadmium. Toxicol Appl Pharmacol. 1981;58:452-460.
10. Jones MM, Basinger MA, Tarka MP. The relative effectiveness of some chelating agents in acute copper intoxication in the mouse. Res Commun Chem Pathol Pharmacol. 1980;27:571-577.
11. Aposhian HV. DMSA and DMPS: water soluble antidotes for heavy metal poisoning. Ann Rev Pharmacol Toxicol. 1983;23: 193-215.
12. Islinger F, Gekle M, Wright SH. Interaction of 2,3-dimercapto-1- propane sulfonate with the human organic anion transporter hOAT1. J Pharmacol Exp Ther. 2001;299:741-747.
13. + -dependent dicarboxylate transporter, NaDC-3 translocates dimethyland disulfhydryl-compounds and contributes to renal heavy metal detoxification. J Am Soc Nephrol. 2002;13:2628-2638.
14. Salmon SE, Sartorelli AC. Cancer chemotherapy. In: Katzung BG, editor. Basic & Clinical Pharmacology. 8th ed. New York: The McGraw-Hill; 2001. p. 923-958.
15. Graziano J, Jones B, Pisciotto P. The effect of heavy metal chelators on the renal accumulation of platinum after cis-dichlorodiammineplatinum II administration to the rat. Br J Pharmacol. 1981;73:649-654.
16. Planas-Bohne F, Shand E, Taylor DM. The effects of dimercaptosuccinic acid and other chelating agents on the retention of platinum in the rat kidney after treatment with cisplatin. Cancer Chemother Pharmacol. 1982;9:120-121.
17. Jones MM, Basinger MA. Control of nephrotoxicity in the rat during repeated cis-platinum treatments. J Appl Toxicol. 1989;9: 229-233.
18. 3.] Shikwa Gakuho. 1986;86:1237-1253. (in Japanese with English abstract)
19. Maehashi H, Murata Y. Arsenic excretion after treatment of arsenic poisoning with DMSA or DMPS in mice. Jpn J Pharmacol. 1986;40:188-190.
20. Waud WR. Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells. Cancer Res. 1987;47:6549-6555.
21. Richards GM. Modifications of the diphenylamine reaction giving increased sensitivity and simplicity in the estimation of DNA. Anal Biochem. 1974;57:369-376.
22. Pokorski PL, McCabe MJJr, Pounds JG. Meso-2,3-dimercaptosuccinic acid induces calcium transients in cultured rhesus monkey kidney cells. Toxicology. 1999;138:81-91.
23. Aposhian HV, Tadlock CH, Moon TE. Protection of mice against lethal effects of sodium arsenite í a quantitative comparison of a number of chelating agents. Toxicol Appl Pharmacol. 1981; 61:385-392.
24. Domingo JL, Bosque MA, Llobet JM, Corbella J. Amelioration by BAL (2,3-dimercapto-1-propanol) and DMPS (sodium 2,3-dimercapto-1-propanesulfonic acid) of arsenite developmental toxicity in mice. Ecotoxicol Environ Saf. 1992;23:274-281.
25. Gomez M, Sanchez DJ, Colomina MT, Domingo JL, Corbella J. Evaluation of the protective activity of 2,3-dimercaptopropanol and sodium 2,3-dimercaptopropane-1-sulfonate on methylmercury-induced developmental toxicity in mice. Arch Environ Contam Toxicol. 1994;26:64-68.
26. Wildenauer DB, Reuther H, Weger N. Interactions of the chelating agent 2,3-dimercaptopropane-1-sulfonate with red blood cells in vitro. I. Evidence for carrier mediated transport. Chem Biol Interact. 1982;42:165-177.
27. Hunter J, Hirst BH, Simmons NL. Epithelial secretion of vinblastine by human intestinal adenocarcinoma cell (HCT-8 and T84) layer expressing P-glycoprotein. Br J Cancer. 1991;64:437-444.
28. Halwachs S, Kneuer C, Honscha W. Endogenous expression of liver-specific drug transporters for organic anions in the rat hepatocytoma fusion cell line HPCT-1E3. Eur J Cell Biol. 2005;84: 677-686.
29. Wlcek K, Svoboda M, Thalhammer T, Sellner F, Krupitza G, Jaeger W. Altered expression of organic anion transporter polypeptide (OATP) genes in human breast carcinoma. Cancer Biol Ther. 2008;7:1450-1455.
30. Shnitsar V, Eckardt R, Gupta S, Grottker J, Müller GA, Koepsell H, et al. Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res. 2009;69:1494-1501.
31. Huang Q, Dunn RTII, Jayadev S, DiSorbo O, Pack FD, Farr SB, et al. Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol Soc. 2001;63:196-207.
32. Yang JM, Chin KV, Haiti WN. Interaction of P-glycoprotein with protein kinase C in human multidrug resistant carcinoma cells. Cancer Res. 1996;56:3490-3494.
33. Miletti-Gonzalez KE, Chen S, Muthukumaran N, Saglimbeni GN, Wu X, Yang JM, et al. The CD44 receptor interacts with Pglycoprotein to promote cell migration and invasion in cancer. Cancer Res. 2005;65:6660-6667.
34. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981;41:1967-1972.
35. Wigler PW, Patterson FK. Reversal agent inhibition of the maultidrug resistance pump in human leukemic lymphoblasts. Biochim Biophys Acta. 1994;1189:1-6.